Program
PARP1 Inhibitor HS-10502
Also written as “HS-10502 + NHA”, “HS-10502 + HS-20093” and “HS-10502+ Apatinib”.
Its studies are mostly in Ovarian Neoplasms, led by Hansoh Pharmaceutical Group.
Furthest: phase 1, since Feb 14, 20232 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 22 open or running | phase 1since Feb 14, 2023 | Feb 14, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2023First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT05740956 · 318 planned · China
- Jan 7, 2025Phase 1 study in Ovarian NeoplasmsNCT06769425 · 157 planned · China
TargetBeta
PARP1 →read by rule
“HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor.”study text, by rule · the study
Other programs on PARP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olaparibrule | AstraZeneca | phase 4 | 78 |
| niraparibrule | GlaxoSmithKline | phase 4 | 43 |
| saruparibrule | AstraZeneca | phase 3 | 14 |
| senaparibrule | impact-therapeutics-inc | phase 2 | 12 |
| nesuparibrule | Jeil Pharmaceutical | phase 2 | 4 |
| palacaparib | AstraZeneca | phase 2 | 3 |
| DM5167rule | digmbio | phase 1 | 1 |
| HSK46256rule | Haisco Pharmaceutical Group | phase 1 | 1 |
| TQB3122 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06769425Ovarian Neoplasms · China | 1 | Recruiting | May 7, 2026 | 157 |
| NCT05740956Ovarian Neoplasms · China | 1 | Recruiting | Apr 1, 2026 | 318 |
How it is read
Names in the registry
- “HS-10502 + NHA”, 1 entry
- “HS-10502 + HS-20093”, 1 entry
- “HS-10502+ Apatinib”, 1 entry
- “HS-10502 + HS-20089”, 1 entry
- “HS-10502 + Platinum + Bevacizumab”, 1 entry
Codes read as this program: HS10502.
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.